ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.0100
-0.0400 (-1.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.0500
Open3.0400
Bid0.0000 x 4000
Ask0.0000 x 3100
Day's Range2.9800 - 3.0700
52 Week Range2.4600 - 3.9600
Volume960,330
Avg. Volume841,017
Market Cap489.486M
Beta (3Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)-0.0370
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.98
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Antares Pharma to Present at the Raymond James 2019 Life Sciences and MedTech Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James 2019 Life Sciences and MedTech Conference on Tuesday, June 18, 2019 at 10:20 a.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • Have Insiders Been Selling Antares Pharma, Inc. (NASDAQ:ATRS) Shares This Year?
    Simply Wall St.14 days ago

    Have Insiders Been Selling Antares Pharma, Inc. (NASDAQ:ATRS) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • GlobeNewswire21 days ago

    Antares Pharma to Present at the Jefferies 2019 Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswirelast month

    Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

    Antares Pharma, Inc. (ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday May 23, 2019 at 1:30 pm Pacific Daylight Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ATRS earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Antares Pharma Inc Earnings Call

  • Investors Who Bought Antares Pharma (NASDAQ:ATRS) Shares Three Years Ago Are Now Up 265%
    Simply Wall St.last month

    Investors Who Bought Antares Pharma (NASDAQ:ATRS) Shares Three Years Ago Are Now Up 265%

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Antares Pharma Inc (ATRS) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Antares Pharma Inc (ATRS) Q1 2019 Earnings Call Transcript

    ATRS earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    Antares Pharma: 1Q Earnings Snapshot

    On a per-share basis, the Ewing, New Jersey-based company said it had a loss of 3 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Antares Pharma Reports First Quarter 2019 Operating and Financial Results

    EWING, N.J., May 02, 2019 -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the first quarter ended March 31, 2019.  The.

  • GlobeNewswire2 months ago

    Antares Pharma to Report First Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its first quarter 2019 financial results and recent operating progress before the market opens on Thursday, May 2, 2019.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on May 2, 2019 to discuss the results. Interested parties may participate in the conference call by dialing 1-800-458-4121 or 1-323-794-2597 and entering access code 2251670.  We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time.  A replay of the conference call will be available from 11:30 a.m. ET on Thursday, May 2, 2019, through 11:30 a.m. ET on Saturday, June 1, 2019 by dialing 1-888-203-1112 or 1-719-457-0820 and entering the access code 2251670.  An archive of the slide presentation will also be available under the “For Investors” section of the Antares Website at www.antarespharma.com.

  • Why Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Pay Matters To You
    Simply Wall St.3 months ago

    Why Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Pay Matters To You

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Bob Apple has been the CEO of Antares Pharma, Inc. (NASDAQ:ATRS) since 2016. This report will, first, examine the...

  • GlobeNewswire3 months ago

    New Research: Key Drivers of Growth for Progress Software, Antares Pharma, National Vision, NMI, Waters, and Kelly Services — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Antares Pharma Announces Receipt of Orphan Drug Designation for the Treatment of Ectopic Pregnancy With Methotrexate

    Antares Pharma, Inc. (ATRS) today announced receipt of orphan drug designation to evaluate the use of subcutaneous methotrexate (“MTX”) for the treatment of ectopic pregnancy that meets predefined criteria for medical management.  Antares plans to initiate a development program utilizing a proprietary auto injector device with doses of methotrexate not commercially approved or available in an auto injector in order to provide potential benefits for both patients and healthcare professionals.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ATRS earnings conference call or presentation 28-Feb-19 1:30pm GMT

    Q4 2018 Antares Pharma Inc Earnings Call

  • GuruFocus.com3 months ago

    Antares Pharma Inc (ATRS) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Antares Pharma Inc is a specialty pharmaceutical company. Antares Pharma Inc had annual average EBITDA growth of 5.50% over the past five years. Warning! GuruFocus has detected 4 Warning Signs with ATRS.

  • AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
    Zacks3 months ago

    AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

    Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.

  • GlobeNewswire3 months ago

    Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 39th Annual Healthcare Conference on Wednesday March 13, 2019 at 8:40 am Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire4 months ago

    Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella

    EWING, N.J., March 04, 2019 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Karen Smith to the Company’s Board of Directors, filling the seat.

  • Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript

    ATRS earnings call for the period ending December 31, 2018.

  • GlobeNewswire4 months ago

    Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

    Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue The Company Reaffirms 2019 Revenue Guidance of $95.0 to $105.0 Million EWING, N.J.,.

  • GlobeNewswire4 months ago

    Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James & Associates 40th Annual Institutional Investors Conference on Tuesday March 5, 2019 at 10:25 am Eastern Time. Antares Pharma, Inc. is a drug device combination products company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire4 months ago

    Antares Pharma to Report Fourth Quarter and Full Year 2018 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its fourth quarter and full year 2018 financial results and recent operating progress before the market opens on Thursday, February 28, 2019.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on February 28, 2019 to discuss the results.

  • Antares Pharma, Inc. (NASDAQ:ATRS): Time For A Financial Health Check
    Simply Wall St.5 months ago

    Antares Pharma, Inc. (NASDAQ:ATRS): Time For A Financial Health Check

    While small-cap stocks, such as Antares Pharma, Inc. (NASDAQ:ATRS) with its market cap of US$484m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...

  • Simply Wall St.6 months ago

    What Kind Of Shareholder Appears On The Antares Pharma, Inc.’s (NASDAQ:ATRS) Shareholder Register?

    If you want to know who really controls Antares Pharma, Inc. (NASDAQ:ATRS), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in Read More...

  • GlobeNewswire6 months ago

    Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors

    Antares Pharma, Inc. (ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors.  Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of Cerecor Inc. (CERC), a biopharmaceutical company focused on neurological and pediatric disorders.  He is also Chairman of the Board at BioDelivery Sciences (BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine.